Please login to the form below

Not currently logged in
Email:
Password:

Lilly Neuroscience

This page shows the latest Lilly Neuroscience news and features for those working in and with pharma, biotech and healthcare.

Lilly posts higher-than-expected profit as new drugs lift outlook

Lilly posts higher-than-expected profit as new drugs lift outlook

diabetes, oncology, immunology and neuroscience,” said David Ricks, Lilly's chairman and CEO. ... Looking forward to 2020, Lilly now expects sales of at least $23.7bn, an increase on previous guidance of $23.6bn.

Latest news

  • Eli Lilly shutters UK neuroscience unit, with 80 job losses expected Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

    Company says decision is not related to Brexit. Eli Lilly has said it plans to shut down its Windlesham research centre in Surrey, UK, which focused on neuroscience R&D, but ... It also said shifting the neuroscience projects to the US will make it

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Lilly's neuroscience R&D portfolio is headed by its Alzheimer's disease (AD) programmes, which include seven candidates headed by AstraZeneca-partnered BACE inhibitor AZD3293, and has recently started phase ... as an attractive partner for external

  • AZ and Lilly start BACE inhibitor trial in Alzheimer's AZ and Lilly start BACE inhibitor trial in Alzheimer's

    AZ and Lilly formed an alliance to develop AZD3293 (also known as LY3314814) back in September, with AZ drawing on Lilly's earlier experience with the emerging drug class. ... Together with Lilly, we have unique expertise that will allow us to evaluate

  • Lilly exploring diabetes portfolio for Alzheimer's potential Lilly exploring diabetes portfolio for Alzheimer's potential

    We're certainly doing some preclinical investigation of the potential of that kind of approach,” Lilly's chief scientific officer for neuroscience Dr Mike Hutton told PMLiVE. ... Read the full interview with Lilly's Dr Mike Hutton in the November issue

  • Lilly launches innovation platform

    Eli Lilly &Company has launched a drug discovery platform focusing on developing treatments in areas of unmet medical need. ... Data reports are then provided for them. In the case of cancer, endocrine, cardiovascular and neuroscience screenings, Lilly

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Nevertheless, unlike some of its peers Lilly has been clear and unwavering in its long-term commitment to neuroscience research. . ... It's at this leafy, Surrey site that I met Lilly's chief scientific officer for neurodegenerative diseases Dr Mike

  • Interview: Jan Lundberg, Eli Lilly Interview: Jan Lundberg, Eli Lilly

    We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories. ... These priorities could be seen in Lilly's own development plans, Lundberg continued, stating that the company had three products each in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...